News|Articles|November 17, 2026

FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC

Author(s)Jonah Feldman
Fact checked by: Sabrina Serani
Listen
0:00 / 0:00

Key Takeaways

  • Accelerated approval covers ALK+ NSCLC previously treated with at least alectinib or with ≥2 prior ALK TKIs plus platinum chemotherapy, based on phase 1/2 ALKOVE-1 efficacy.
  • In 253 TKI-pretreated patients, ORR was 31% with 2% CRs; median DOR was not reached, and median PFS was 5.7 months by independent central review.
SHOW MORE

The FDA has approved neladalkib for TKI-pretreated advanced ALK-positive NSCLC based on ALKOVE-1, requiring only 1 prior line of treatment in those who received prior alectinib.

The FDA has granted accelerated approval to neladalkib (NVL-655; Nelkarmi), an ALK-selective tyrosine kinase inhibitor (TKI), for adult patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC) who have received at least 1 prior ALK TKI consisting of alectinib or 2 prior ALK TKIs and platinum-based chemotherapy.1

Among 67 patients who had received 1 prior ALK TKI consisting of alectinib, the overall response rate (ORR) was 49%, with 76% of responders having a duration of response (DOR) of at least 6 months and 52% having a DOR of at least 1 year. Among 155 patients who received 2 or more prior TKIs and chemotherapy, the ORR was 32%, with 69% of responders demonstrating a 6-month or longer DOR and 51% showing a 1-year or longer DOR.1

The approval is based on results from the phase 1/2 ALKOVE-1 trial (NCT05384626).1,2

“Advances in treatment have brought us closer to the goal of managing ALK-positive lung cancer as a chronic condition, but balancing disease control and long-term tolerability remains a significant challenge. The approval of neladalkib provides an important new treatment option for patients,” stated Alice Shaw, MD, PhD, an ALKOVE-1 trial investigator and chair of the Department of Medical Oncology and chief of Strategic Partnerships at Dana-Farber Cancer Institute, in a news release.3


Trial Design and Population

ALKOVE-1 is a global, first-in-human phase 1/2 trial. Its phase 2 portion enrolled patients with advanced ALK-positive NSCLC into cohorts defined by prior ALK TKI exposure and treated them with neladalkib at the recommended phase 2 dose of 150 mg once daily. The primary end point was ORR by blinded independent central review.

The pivotal population included patients treated by September 30, 2024, with measurable disease, and the data cutoff was August 29, 2025. Patients in the pivotal population had a median age of 56 years and had received a median of 3 prior anticancer therapies (range, 1-11); 51% had received chemotherapy, and 95% had received a second-generation ALK TKI, with 75% having received lorlatinib (Lorbrena). Baseline CNS metastases were present in 40%, and 19% had an ALK G1202R mutation.

The recommended dosage is 150 mg orally once daily with or without food until disease progression or unacceptable toxicity.

Efficacy by Prior Treatment

In the 253 patients with TKI-pretreated ALK-positive NSCLC who made up the pivotal efficacy population with findings presented previously, the ORR by blinded independent central review was 31% (95% CI, 26%-37%), including complete responses in 2%. Median DOR had not been reached (95% CI, 14.5-not estimable) at a median follow-up of 11.3 months, and median progression-free survival (PFS) was 5.7 months (95% CI, 4.4-6.5).2

Responses were more likely in patients who had not received lorlatinib. Among 63 lorlatinib-naive patients, the ORR was 46% (95% CI, 33%-59%) and median PFS was 14.5 months (95% CI, 4.8-not estimable). Among 190 lorlatinib-exposed patients, the ORR was 26% (95% CI, 20%-33%), the median DOR was 17.6 months (95% CI, 6.9-not estimable), and median PFS was 4.6 months (95% CI, 2.8-6.2).

In 47 patients with the ALK G1202R resistance mutation, the ORR was 68% (95% CI, 53%-81%), including 63% in those previously treated with lorlatinib. Among 92 patients with measurable central nervous system (CNS) lesions, the intracranial ORR was 32% (95% CI, 22%-42%): 63% in lorlatinib-naive patients and 21% in lorlatinib-exposed patients.

Safety Profile

Among 656 patients with ALK-positive NSCLC treated at the recommended dose, with a median exposure of 6.0 months, the most common treatment-emergent adverse events (TEAEs) were increased alanine aminotransferase (ALT; 47%; grade ≥3, 20%), increased aspartate aminotransferase (AST; 44%; grade ≥3, 16%), constipation (28%), dysgeusia (23%), peripheral edema (18%), cough (16%), and nausea (16%).

TEAEs led to dose reduction in 17% of patients, most often for increased ALT (10%) or AST (8%), and to discontinuation in 5%. The investigators reported that transaminase elevations were mostly asymptomatic, transient, and reversible with dose interruption or reduction, and that preliminary data suggested higher incidence in less heavily pretreated patients.2

The prescribing information includes warnings and precautions for liver and kidney toxicity, ocular toxicity, creatine phosphokinase elevation, and embryo-fetal toxicity.1

Regulatory and Development Context

The FDA granted the new drug application priority review in May 2026. Neladalkib previously received breakthrough therapy designation for patients with locally advanced or metastatic ALK-positive NSCLC previously treated with 2 or more ALK TKIs, as well as orphan drug designation for ALK-positive NSCLC.4

In preliminary data from 44 TKI-naive patients in ALKOVE-1, the ORR was 86%.2 Neladalkib is being compared with alectinib (Alecensa) in that setting in the randomized phase 3 ALKAZAR trial (NCT06765109), whose protocol includes enhanced liver function monitoring and earlier dose interventions.2

REFERENCES
1. FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer. FDA. November 17, 2026. Accessed November 17, 2026. https://tinyurl.com/yu97b3j3
2. Lin JJ, Felip E, Cho BC, et al. ALKOVE-1: efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC. J Clin Oncol. 2026;44(suppl 16):8503. doi:10.1200/JCO.2026.44.16_suppl.8503
3. Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer. News release. GSK. November 17, 2026. Accessed November 17, 2026. https://tinyurl.com/4czpxdsm
4. Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC. News release. Nuvalent Inc. May 27, 2026. Accessed November 4, 2026. https://tinyurl.com/x6fv7bxn

Related to this article